Inarigivir soproxil - Spring Bank Pharmaceuticals

Drug Profile

Inarigivir soproxil - Spring Bank Pharmaceuticals

Alternative Names: Inarigivir; SB-9200

Latest Information Update: 07 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Spring Bank Pharmaceuticals
  • Developer National Institutes of Health (USA); Spring Bank Pharmaceuticals
  • Class Antivirals; Nucleotides; Small molecules
  • Mechanism of Action DDX58 protein stimulants; Immunostimulants; NOD2 protein antagonists; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Hepatitis C

Highest Development Phases

  • Phase II Hepatitis B
  • Phase I Hepatitis C
  • Preclinical Norovirus infections; Respiratory syncytial virus infections
  • Research Dengue; Japanese encephalitis; West Nile virus infections
  • Suspended Hepatitis D; HIV infections

Most Recent Events

  • 01 Nov 2017 Chemical structure information added
  • 24 Oct 2017 Efficacy data from the phase II ACHIEVE trial in Hepatitis B presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2017)
  • 20 Oct 2017 Updated efficacy data from the phase II ACHIEVE trial in Hepatitis B released by Spring Bank Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top